Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma.
Adrenal Cortex Neoplasms
/ metabolism
Adrenocortical Carcinoma
/ metabolism
Biomarkers, Tumor
/ genetics
Combined Modality Therapy
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Humans
Male
Middle Aged
Prognosis
Receptors, CXCR
/ genetics
Receptors, CXCR4
/ genetics
Survival Rate
Tumor Cells, Cultured
CXCR4
CXCR7
adrenocortical carcinoma
chemokine receptor
prognosis
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
08
2020
accepted:
20
10
2020
entrez:
7
12
2020
pubmed:
8
12
2020
medline:
4
6
2021
Statut:
epublish
Résumé
Chemokine receptors have a negative impact on tumor progression in several human cancers and have therefore been of interest for molecular imaging and targeted therapy. However, their clinical and prognostic significance in adrenocortical carcinoma (ACC) is unknown. The aim of this study was to evaluate the chemokine receptor profile in ACC and to analyse its association with clinicopathological characteristics and clinical outcome. A chemokine receptor profile was initially evaluated by quantitative PCR in 4 normal adrenals, 18 ACC samples and human ACC cell line NCI-H295. High expression of CXCR4 and CXCR7 in both healthy and malignant adrenal tissue and ACC cells was confirmed. In the next step, we analyzed the expression and cellular localization of CXCR4 and CXCR7 in ACC by immunohistochemistry in 187 and 84 samples, respectively. These results were correlated with clinicopathological parameters and survival outcome. We detected strong membrane expression of CXCR4 and CXCR7 in 50% of ACC samples. Strong cytoplasmic CXCR4 staining was more frequent among samples derived from metastases compared to primaries (
Identifiants
pubmed: 33281749
doi: 10.3389/fendo.2020.597878
pmc: PMC7691376
doi:
Substances chimiques
ACKR3 protein, human
0
Biomarkers, Tumor
0
CXCR4 protein, human
0
Receptors, CXCR
0
Receptors, CXCR4
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
597878Informations de copyright
Copyright © 2020 Chifu, Heinze, Fuss, Lang, Kroiss, Kircher, Ronchi, Altieri, Schirbel, Fassnacht and Hahner.
Références
Lung Cancer. 2010 Jun;68(3):466-71
pubmed: 19716197
ChemMedChem. 2011 Oct 4;6(10):1789-91
pubmed: 21780290
Clin Cancer Res. 2014 Jul 1;20(13):3581-8
pubmed: 24727324
FASEB J. 2019 May;33(5):6596-6608
pubmed: 30802149
J Immunother Cancer. 2020 May;8(1):
pubmed: 32474412
J Nucl Med. 2019 Oct;60(10):1399-1405
pubmed: 30850502
Int J Oncol. 2009 Feb;34(2):473-80
pubmed: 19148483
J Clin Endocrinol Metab. 2015 Mar;100(3):841-9
pubmed: 25559399
Int J Radiat Biol. 2014 Aug;90(8):687-99
pubmed: 24650104
J Transl Med. 2013 Sep 30;11:238
pubmed: 24074251
Theranostics. 2017 Jun 11;7(9):2350-2362
pubmed: 28744319
Antivir Chem Chemother. 2019 Jan-Dec;27:2040206619829382
pubmed: 30776910
J Oncol. 2019 Apr 1;2019:6072863
pubmed: 31057613
Curr Med Chem. 2019;26(17):3026-3041
pubmed: 28875842
Oncotarget. 2015 Mar 10;6(7):5022-40
pubmed: 25669980
EXCLI J. 2016 Feb 15;15:134-43
pubmed: 27092040
Front Immunol. 2018 Dec 21;9:3018
pubmed: 30622535
J Nucl Med. 2016 Jun;57(6):981-8
pubmed: 26912435
Cell Mol Immunol. 2018 Apr;15(4):299-311
pubmed: 29082918
Mol Imaging. 2014;13:
pubmed: 25341373
Clin Nucl Med. 2017 Jan;42(1):e29-e34
pubmed: 27819856
Best Pract Res Clin Endocrinol Metab. 2020 May;34(3):101434
pubmed: 32622829
Onco Targets Ther. 2013 Sep 30;6:1347-61
pubmed: 24124379
Development. 2014 Nov;141(22):4199-205
pubmed: 25371357
Hypertension. 2018 Feb;71(2):317-325
pubmed: 29279316
Front Endocrinol (Lausanne). 2017 Mar 23;8:52
pubmed: 28386245
Eur J Cancer. 2013 Jan;49(1):219-30
pubmed: 22683307
Endocr Relat Cancer. 2015 Aug;22(4):531-43
pubmed: 25979380
Breast Cancer Res. 2011;13(6):R128
pubmed: 22152016
Cancer. 2009 Jan 15;115(2):243-50
pubmed: 19025987
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4558-4566
pubmed: 30700545
PLoS One. 2010 Feb 11;5(2):e9175
pubmed: 20161793
J Pathol Transl Med. 2018 Nov;52(6):369-377
pubmed: 30269472
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Blood. 2012 Apr 26;119(17):3917-24
pubmed: 22308295
Anal Cell Pathol (Amst). 2015;2015:891020
pubmed: 26161302
Cancer Metastasis Rev. 2010 Dec;29(4):709-22
pubmed: 20839032
Adv Cancer Res. 2014;124:31-82
pubmed: 25287686
Trends Mol Med. 2013 Jan;19(1):12-22
pubmed: 23153575
Br J Cancer. 2017 Dec 5;117(12):1837-1845
pubmed: 29112684
Hepatology. 2015 May;61(5):1591-602
pubmed: 25529917
Endocr Connect. 2018 Dec;7(12):E5-E8
pubmed: 30400026
Clin Cancer Res. 2015 Oct 1;21(19):4278-85
pubmed: 26199389
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):12997-13002
pubmed: 30514817
J Med Chem. 2011 Nov 10;54(21):7648-62
pubmed: 21905730
PLoS One. 2008;3(12):e4069
pubmed: 19116653
Blood. 2009 Jun 11;113(24):6206-14
pubmed: 19050309
Oncotarget. 2017 Feb 7;8(6):9323-9338
pubmed: 28030838
Clin Cancer Res. 2019 Jul 1;25(13):3934-3945
pubmed: 30940657
Ann Nucl Med. 2018 Oct;32(8):503-511
pubmed: 30105558
Eur J Endocrinol. 2018 Feb;178(2):181-188
pubmed: 29187510
Nat Rev Immunol. 2017 Sep;17(9):559-572
pubmed: 28555670
J Nucl Med. 2011 Nov;52(11):1803-10
pubmed: 22045709
BMC Cancer. 2008 Nov 23;8:340
pubmed: 19025611
Theranostics. 2020 Jul 9;10(18):8264-8280
pubmed: 32724470
Oncotarget. 2017 Aug 4;8(43):73387-73406
pubmed: 29088715
Front Immunol. 2019 Mar 06;10:379
pubmed: 30894861